Akura Medical, a Los Gatos, CA-based company focused on advancing differentiated approach to effectively address the major challenges of venous thromboembolism (VTE), closed a $35M Series B financing.
The round was led by The Capital Partnership (TCP) and Cormorant Asset Management, with significant participation from the PA MedTech VC Fund, AMED Ventures, Lilly Asia Ventures, Unorthodox Ventures and Shifamed angel investors.
The company intends to use the funds to apply for FDA 510(k) clearance for the Akura Mechanical Thrombectomy Platform, support clinical trials for additional indications, and scale manufacturing capabilities.
Led by Murali Srivathsa, President and Chief Executive Officer, Akura provides a mechanical thrombectomy platform designed to be a small bore system. The low-profile, steerable sheath allows physicians to bring the tip of the catheter directly to the proximal end of the clot without having to cross the clot. The platform’s integrated aspiration and maceration technology, incorporating intersecting jets, aims to enable efficient removal of mixed morphology clots. Additionally, pressure sensors provide real-time hemodynamic data, reducing the guesswork around case progress.
Akura Medical is a privately held portfolio company of Shifamed LLC.
FinSMEs
03/10/2023